Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy.

Fiche du document

Auteurs
Date

2003

Type de document
Périmètre
Langue
Identifiants
Source

Serveur académique Lausannois

Relations

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1161/01.CIR.0000080735.93327.00

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/12821538

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1524-4539

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_3A50A6EB875D1

Collection

Serveur Académique Lausannois

Organisation

Université de Lausanne et CHUV

Licences

info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer

Mots-clés 0

Adult; Aged; Animals; Antigens, CD36/metabolism; Astrocytes/drug effects; Astrocytes/enzymology; Cell Division/drug effects; Cells, Cultured; Cyclooxygenase 2; Diabetic Retinopathy/complications; Diabetic Retinopathy/drug therapy; Dinoprostone/metabolism; Disease Models, Animal; Endothelial Growth Factors/metabolism; Enzyme Inhibitors/pharmacology; Female; Humans; Intercellular Signaling Peptides and Proteins/metabolism; Ischemia/complications; Ischemia/enzymology; Isoenzymes/antagonists & inhibitors; Isoenzymes/metabolism; Lymphokines/metabolism; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Middle Aged; Neovascularization, Pathologic/drug therapy; Neovascularization, Pathologic/pathology; Prostaglandin-Endoperoxide Synthases/metabolism; Rats; Rats, Sprague-Dawley; Receptors, Immunologic; Receptors, Lipoprotein/metabolism; Receptors, Prostaglandin E/drug effects; Receptors, Prostaglandin E/metabolism; Receptors, Prostaglandin E, EP3 Subtype; Receptors, Prostaglandin E, EP4 Subtype; Receptors, Scavenger; Retina/drug effects; Retina/enzymology; Retinal Vessels/drug effects; Retinal Vessels/pathology; Thrombospondin 1/metabolism; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2/metabolism; Vascular Endothelial Growth Factors; Vitreoretinopathy, Proliferative/complications; Vitreoretinopathy, Proliferative/drug therapy

Sujets proches En

Angiogenesis

Citer ce document

F. Sennlaub et al., « Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy. », Serveur académique Lausannois, ID : 10.1161/01.CIR.0000080735.93327.00

Métriques

Partage / Export

Résumé 0

BACKGROUND: Intravitreal neovascular diseases, as in ischemic retinopathies, are a major cause of blindness. Because inflammatory mechanisms influence vitreal neovascularization and cyclooxygenase (COX)-2 promotes tumor angiogenesis, we investigated the role of COX-2 in ischemic proliferative retinopathy. METHODS AND RESULTS: We describe here that COX-2 is induced in retinal astrocytes in human diabetic retinopathy, in the murine and rat model of ischemic proliferative retinopathy in vivo, and in hypoxic astrocytes in vitro. Specific COX-2 but not COX-1 inhibitors prevented intravitreal neovascularization, whereas prostaglandin E2, mainly via its prostaglandin E receptor 3 (EP3), exacerbated neovascularization. COX-2 inhibition induced an upregulation of thrombospondin-1 and its CD36 receptor, consistent with the observed antiangiogenic effects of COX-2 inhibition; EP3 stimulation reversed effects of COX-2 inhibitors on thrombospondin-1 and CD36. CONCLUSIONS: These findings point to an important role for COX-2 in ischemic proliferative retinopathy, as in diabetes.

document thumbnail

Par les mêmes auteurs

Sur les mêmes sujets

Exporter en